CD
CDIO.US Cardio Diagnostics Holdings Inc
- Market cap
- USD 5.59M
- P/E
- -
- P/B
- 0.98x
- ROE
- -117.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CDIO.US undervalued?
Graham numberThe Graham number of Cardio Diagnostics Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cardio Diagnostics Holdings Inc fundamental analysis
No fundamental analysis for Cardio Diagnostics Holdings Inc yet.
Cardio Diagnostics Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic…
Full company profileCardio Diagnostics Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cardio Diagnostics Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 901.00 | 950.00 | 17.1K | 34.9K | 14.8K | 15.5K |
| Gross Profit | - | 901.00 | 950.00 | 17.1K | 34.9K | 14.8K | -111K |
| Operating Income | -609K | -620K | -4.55M | -7.24M | -8.37M | -6.48M | -6.68M |
| EBITDA | -598K | -604K | -4.64M | -1.53M | -8.09M | -6.09M | -6.43M |
| Net Income | -605K | -620K | -4.66M | -8.38M | -8.38M | -6.50M | -6.70M |
| EPS | -0.06 | -1.96 | -1.51 | -20 | -0.31 | -3.71 | -2.26 |
| Balance Sheet | |||||||
| Total Assets | 446K | 1.10M | 6.25M | 4.46M | 10.6M | 7.77M | 6.08M |
| Total Liabilities | 386K | 33.9K | 1.95M | 1.50M | 1.06M | 793K | 366K |
| Shareholders' Equity | 60.4K | 1.07M | 4.30M | 2.96M | 9.56M | 6.97M | 5.72M |
| Cash & Short-term Investments | 237K | 513K | 4.12M | 1.28M | 7.83M | 5.11M | 3.94M |
| Total Debt | - | - | 849K | 1.26M | 970K | 696K | 239K |
| Cash Flow | |||||||
| Operating Cash Flow | 25.9K | -585K | -5.09M | -5.67M | -4.99M | -5.73M | -5.89M |
| Capital Expenditure | 29.9K | 114K | 76.2K | 794K | 404K | 187K | 2.36K |
| Free Cash Flow | -4.05K | -699K | -5.17M | -6.47M | -5.40M | -5.91M | -5.90M |
| Ratios | |||||||
| ROE | -1,002.5% | -58.1% | -108.4% | -283.2% | -87.7% | -93.2% | -117.1% |
| ROA | -135.6% | -56.3% | -74.6% | -187.7% | -79.0% | -83.7% | -110.1% |
| Net Profit Margin | - | -68,862.2% | -490,630.0% | -49,087.8% | -24,028.2% | -43,832.5% | -43,181.0% |
| Debt to Equity | - | - | 0.20x | 0.43x | 0.10x | 0.10x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cardio Diagnostics Holdings Inc dividends
Cardio Diagnostics Holdings Inc has not paid dividends in the last 6 fiscal years.
Last stock split: 1:30 on May 13, 2025.
Who owns Cardio Diagnostics Holdings Inc
- Insiders 8.31%
- Institutions 6.52%
- Public & others 85.17%
- Shares outstanding 2.96M
- Free float 2.84M
Top funds holding CDIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 15.7K | 0.53% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.83K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 2.25K | 0.08% | 0.00% | Sep 2026 |
Top institutions holding CDIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Renaissance Technologies Corp | 49.2K | 1.66% | +220.56% | Jun 2026 |
| BlackRock Inc | 34.7K | 1.17% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 26.2K | 0.89% | -18.47% | Jun 2026 |
| Vanguard Capital Management, LLC | 20.2K | 0.68% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 19.1K | 0.64% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 16.1K | 0.54% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 11.9K | 0.40% | -85.32% | Jun 2026 |
| State Street Corp | 10.1K | 0.34% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 2.82K | 0.10% | -28.85% | Jun 2026 |
| Tower Research Capital LLC | 1.81K | 0.06% | -17.47% | Jun 2026 |
| UBS Group AG | 656.00 | 0.02% | -93.39% | Jun 2026 |
| Wolverine Asset Management LLC | 104.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 100.00 | 0.00% | 0.00% | Jun 2026 |
| SHP Wealth Management | 16.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 16.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 10.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Scientech Research LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| HRT FINANCIAL LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Cardio Diagnostics Holdings Inc company profile
- Company name
- Cardio Diagnostics Holdings Inc
- Ticker
- CDIO.US
- Exchange
- USA Stocks
- Listed since
- Jan 14, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- 311 West Superior Street, Chicago, IL, United States, 60654
- Phone
- 855 226 9991
- Website
- cdio.ai
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Cardio Diagnostics Holdings Inc management
4- Dr. Meeshanthini V. Dogan Ph.D.Co-Founder, CEO & Director · born 1989
- Ms. Elisa Michael Luqman Esq., J.D., M.B.A.CFO & Principal Accounting Officer · born 1964
- Mr. Timur Dogan Ph.D.Chief Technology Officer · born 1989
- Dr. Robert A. Philibert M.D., Ph.D.Co-Founder, Chief Medical Officer & Director · born 1962